Prospect News: News for Axcan Pharma Inc.

E-mail us: service@prospectnews.com Or call: 212 374 2800

Bank Loans - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products

Add to balance / Manage account

Not logged in

Prospect News home > Main news index > All issuers starting with A > All stories on Axcan Pharma Inc.

Search again

Enter part or all of the issuer name:

Market:

All markets No structured products Bank loans Canadian bonds CLOs Convertibles Distressed debt Emerging markets High yield Investment grade Liability management Municipals PIPEs Preferreds Private placements All leveraged markets Structured products

Market: BK = Bank loans, CV = Convertibles, DD = Distressed Debt, EM = Emerging Markets, HY = High Yield, IG = Investment Grade, LM = Liability Management, MU = Municipals, PP = PIPEs, PF = Preferreds, PV = Private Placements, SP = Structured Products
Recent items, highlighted in orange, are $4.00 each. All others are $1.00 each. Headlines in gray are not currently covered by your subscription.

Axcan Pharma Inc.

4/14/2010	BKHY	Moody's reviews Axcan
3/27/2009	BKHY	Moody's lifts Axcan to SLG-1
2/18/2009	HY	S&P upgrades Axcan
12/31/2008	SS	Axcan sets meeting date for merger vote
12/31/2008	BKHY	Axcan buyout financing to include $475 million credit facility, $275 million bonds
9/17/2008	HY	S&P rates Axcan B+
5/1/2008	HY	Market Commentary: Range Resources prices deal; Amkor, Visteon continue rising; funds see $297 million inflow
4/30/2008	HY	New Issue: Axcan prices $235 million 123/4% eight-year senior notes at 98.84 to yield 13%
4/30/2008	HY	Market Commentary: Axcan Pharma prices eight-year deal, then moves up; Visteon leads auto parts names higher; Six Flags flies
4/29/2008	HY	Axcan Pharma sets price talk for $235 million eight-year notes at 13% area
4/29/2008	HY	Market Commentary: Macrovision prices five-year; new Ford Credit notes firm smartly; Univision gains on Televisa trial delay
4/28/2008	HY	Market Commentary: Ford Credit sells giant deal, parent up on Tracinda news; MarkWest adds on; Cott off as results disappoint
4/28/2008	HY	Axcan Pharma revives $235 million offering of eight-year senior notes
2/25/2008	BK	Market Commentary: Cash, LCDX gain ground; Swift dips on FBI raid rumors; Solutia reaches agreement on exit financing
2/25/2008	SS	Axcan Pharma acquired; stock ceases trading
2/22/2008	BKHY	Moody's rates Axcan loans, notes Ba2
2/22/2008	HY	Market Commentary: CHC Helicopter flies on takeover news; Mobile Mini dives; little impact from GMAC/ResCap downgrade
2/22/2008	BK	Axcan ups term loan A to $175 million, cuts revolver to $115 million
2/22/2008	BK	Market Commentary: TXU, Georgia-Pacific inch higher; Dayton extends deadline; Press Ganey nets interest
2/15/2008	HY	Market Commentary: Junk easier in pre-holiday trade; builders steady before downgrade; Nuveen easier on monoline turmoil
2/14/2008	HY	Market Commentary: Goodman sells private deal; Goodyear up on good numbers; GMAC off on warning; funds add $3 million
2/14/2008	SS	Axcan, TPG Capital transaction receives final regulatory approval
2/13/2008	HY	New Issue: Axcan prices $228 million 91/4% secured notes, abandons $235 million unsecured note offering
2/13/2008	HY	Market Commentary: Axcan Pharma prices a tranche; Hawker Beechcraft, Amkor gain on numbers; Idearc bounces back
2/12/2008	HY	Axcan Pharma sets talk for restructured $460 million two-part note offering
2/12/2008	HY	Market Commentary: Levi Strauss better on earnings; GM mixed in active dealings after numbers; Idearc finds a bottom
2/11/2008	HY	Market Commentary: Directory names continue slide amid generally heavy market; casinos off; GM up ahead of quarterly results
2/11/2008	HY	Market Commentary: Directory names continue slide amid generally heavy market; casinos off; GM up ahead of quarterly results
2/11/2008	BK	Axcan eliminates $385 million term loan B, adds $165 million term loan A
2/11/2008	BK	Market Commentary: Axcan reworks structure; Tropicana dips as revenues fall; $460 million BWIC sells; LCDX slides
2/11/2008	HY	Axcan Pharma upsizes bonds to $460 million, replaces term loan B with secured notes tranche
2/8/2008	HY	Market Commentary: Idearc, other directory bonds slide again; Freescale off as CEO exits; funds see $142 million inflow
2/5/2008	HY	Market Commentary: Junk market ends off, but no rout; builders up as Standard Pacific gains; casinos a losing bet
2/4/2008	HY	Market Commentary: Football hangover stills trading; acquisitive Freescale gyrates; builders, retailers gain; Solutia eases terms
2/1/2008	BK	Axcan launches $475 million credit facility at Libor plus 350 bps
2/1/2008	BK	Market Commentary: Goodman outlines potential changes; Delphi mulling modifications; Axcan sets talk; PanAmSat inches up
2/1/2008	HY	Market Commentary: Petroleum Development deal prices; Freescale continues rebound; junk market generally firmer
1/31/2008	HY	Axcan to start roadshow Friday for $240 million eight-year senior notes
1/31/2008	HY	Market Commentary: Freescale firmer after numbers; Ford Credit gets clocked; retailers recover; funds see $78 million outflow
1/31/2008	HY	Market Commentary: Freescale firmer after numbers; Ford Credit gets clocked; retailers recover; funds see $78 million outflow
1/29/2008	BK	Axcan sets Thursday launch for $475 million credit facility
1/28/2008	SS	Quebec court OKs Axcan acquisition
1/25/2008	BKCVHY	Moody's rates Axcan loans Ba2, notes B3
1/25/2008	SS	Axcan Pharma shareholders OK acquisition by TPG Capital
1/24/2008	BKHY	S&P rates Axcan loans BB-, notes B-
1/24/2008	HY	Axcan Pharma's $275 million eight-year notes to come via Banc of America
1/7/2008	SS	Axcan, TPG deal granted early termination of HSR waiting period
12/5/2007	SS	Pennant Capital says Axcan Pharma owes shareholders more information on deal with TPG Capital
12/4/2007	BK	Axcan $750 million LBO debt financing to include new credit facility
11/29/2007	BK	Axcan to get debt financing for purchase by TPG
6/29/2007	CV	Axcan investors convert all $125 million of 4.25% notes ahead of redemption
5/15/2007	CV	Axcan Pharma calls 4.25% convertibles
5/10/2007	CV	Axcan to redeem 4.25% convertibles
9/26/2006	BT	Axcan, AGI sign development deal for reflux disease therapies
9/21/2006	BT	Axcan sees acquisitions, Helizide launch, expansions in Europe as growth drivers
9/21/2006	BT	Merrill keeps Axcan at neutral
9/20/2006	BT	Axcan says itopride fails to meet goals in second phase 3 trial for functional dyspepsia
8/11/2006	BT	Axcan rated at neutral by Merrill
8/10/2006	BT	Axcan updates product pipeline, sees third-quarter revenues rise 29%
8/1/2006	BT	Axcan kept at neutral by Merrill
6/29/2006	BT	Axcan at neutral by Merrill
6/28/2006	BT	Axcan, FDA to determine effect of ITAX phase 2, phase 3 trial data on next phase 3 study
6/22/2006	BT	Axcan upgraded to neutral by Merrill
5/8/2006	BT	Axcan rated at neutral by Merrill
5/5/2006	BT	Axcan given a neutral rating by Merrill
4/28/2006	BT	Axcan kept at neutral by Merrill
3/29/2006	BT	Axcan submits FDA amendment to its New Drug Application for Helizide
3/23/2006	BT	Merrill ups Axcan Pharma to neutral
3/13/2006	BT	Axcan kept at sell by Merrill
2/28/2006	BT	Axcan at sell by Merrill
2/22/2006	BT	Axcan releases disappointing results for ITAX phase 3 clinical study
2/22/2006	BT	Axcan downgraded to sell by Merrill
2/22/2006	BT	Market Commentary: Axcan annihilated; Lexicon lifted; Advanced Magnetics draws interest; CombiMatrix climbs
2/21/2006	BT	Merrill keeps Axcan at neutral
2/10/2006	BT	Merrill puts Axcan at neutral
2/1/2006	BT	Axcan unchanged at neutral by Merrill
12/15/2005	BT	Axcan passes enrollment target for phase 3 trial of ITAX for functional dyspepsia
11/11/2005	BT	Merrill Lynch maintains Axcan at neutral
11/2/2005	BT	Merrill keeps Axcan Pharma neutral
8/12/2005	BT	Axcan dropped to neutral by Merrill
9/10/2004	CV	Merrill: Regal-Beloit, Axcan, Global Imaging convertibles would suffer biggest price correction in takeover event
3/5/2003	CV	Axcan says greenshoe exercised, raising convertibles to $125 million
3/4/2003	CV	Market Commentary: Inco deals steady out of gate; Watson trading up in gray as credit, put offset pricey terms
2/28/2003	CV	Market Commentary: LNR, Chesapeake, Axcan rise; buyers for Gap's convertibles as stock slides on sales news
2/28/2003	CV	New Issue: Axcan upsized $110 million convertibles yield 4.25%, up 38%
2/27/2003	CV	Market Commentary: New issues dominate market as funding window narrows
2/26/2003	CV	Market Commentary: New issues bid up in gray; Tyco's new converts gain sharply, power names dive
2/25/2003	CV	Axcan Pharma $100 million convertible talked to yield 4.25-4.75%, up 25-30%
2/25/2003	CV	Market Commentary: Credit markets, new deals stir players out of shadows
2/24/2003	CV	Market Commentary: Very slow trading day, with players hanging in shadows
2/24/2003	CV	Axcan Pharma plans $100 million convertible

©2025 Prospect News. This page is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies, faxing, photocopying or any other form of reproduction.